Merck and Eisai study various combinations of their cancer drugs
Executive Summary
Merck & Co. Inc. signed an agreement to combine Keytruda (pembrolizumab; MK3475) with two Eisai Co. Ltd. drugs: Lenvima (lenvatinib; E7080; ER20349200) and Halaven (eribulin; E7389; NSC70738).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice